Wuhan Keqian Biology Co Ltd
SSE:688526

Watchlist Manager
Wuhan Keqian Biology Co Ltd Logo
Wuhan Keqian Biology Co Ltd
SSE:688526
Watchlist
Price: 17.05 CNY 0.35% Market Closed
Market Cap: 7.9B CNY
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+47%
Revenue
Forecast
-34%
Operating Income
Forecast
+10%
Net Income
Forecast
+3%

Wall Street
Price Targets

Price Targets Summary
Wuhan Keqian Biology Co Ltd

Wall Street analysts forecast Wuhan Keqian Biology Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Wuhan Keqian Biology Co Ltd is 22.06 CNY with a low forecast of 20.2 CNY and a high forecast of 24.41 CNY.

Lowest Forecast
Wall Street Target
20.2 CNY
18% Upside
Average Forecast
Wall Street Target
22.06 CNY
29% Upside
Highest Forecast
Wall Street Target
24.41 CNY
43% Upside
Lowest
Price Target
20.2 CNY
18% Upside
Average
Price Target
22.06 CNY
29% Upside
Highest
Price Target
24.41 CNY
43% Upside
Wuhan Keqian Biology Co Ltd Competitors:
Price Targets
4568
Daiichi Sankyo Co Ltd
61% Upside
128940
Hanmi Pharm Co Ltd
15% Upside
000999
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
29% Upside
NEULANDLAB
Neuland Laboratories Ltd
56% Upside
4568
Daiichi Sankyo Co Ltd
61% Upside
128940
Hanmi Pharm Co Ltd
15% Upside
000999
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
29% Upside
NEULANDLAB
Neuland Laboratories Ltd
56% Upside
VENUSREM
Venus Remedies Ltd
6% Downside
HITI
High Tide Inc
126% Upside
Z
300357
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
36% Upside
600276
Jiangsu Hengrui Pharmaceuticals Co Ltd
8% Upside

Revenue
Forecast

Revenue Estimate
Wuhan Keqian Biology Co Ltd

For the last 6 years the compound annual growth rate for Wuhan Keqian Biology Co Ltd's revenue is 4%. The projected CAGR for the next 3 years is 15%.

4%
Past Growth
15%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Wuhan Keqian Biology Co Ltd

For the last 6 years the compound annual growth rate for Wuhan Keqian Biology Co Ltd's operating income is -4%. The projected CAGR for the next 1 year is 47%.

-4%
Past Growth
47%
Estimated Growth
Estimates Accuracy
-13%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Wuhan Keqian Biology Co Ltd

For the last 6 years the compound annual growth rate for Wuhan Keqian Biology Co Ltd's net income is 0%. The projected CAGR for the next 2 years is 14%.

0%
Past Growth
14%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Wuhan Keqian Biology Co Ltd's stock price target?
Price Target
22.06 CNY

According to Wall Street analysts, the average 1-year price target for Wuhan Keqian Biology Co Ltd is 22.06 CNY with a low forecast of 20.2 CNY and a high forecast of 24.41 CNY.

What is Wuhan Keqian Biology Co Ltd's Revenue forecast?
Projected CAGR
15%

For the last 6 years the compound annual growth rate for Wuhan Keqian Biology Co Ltd's revenue is 4%. The projected CAGR for the next 3 years is 15%.

What is Wuhan Keqian Biology Co Ltd's Operating Income forecast?
Projected CAGR
47%

For the last 6 years the compound annual growth rate for Wuhan Keqian Biology Co Ltd's operating income is -4%. The projected CAGR for the next 1 year is 47%.

What is Wuhan Keqian Biology Co Ltd's Net Income forecast?
Projected CAGR
14%

For the last 6 years the compound annual growth rate for Wuhan Keqian Biology Co Ltd's net income is 0%. The projected CAGR for the next 2 years is 14%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 258,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.